Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 11
1988 31
1989 51
1990 89
1991 111
1992 124
1993 128
1994 120
1995 99
1996 103
1997 97
1998 83
1999 70
2000 72
2001 47
2002 50
2003 46
2004 56
2005 49
2006 40
2007 45
2008 35
2009 18
2010 31
2011 37
2012 36
2013 39
2014 27
2015 35
2016 18
2017 27
2018 31
2019 31
2020 28
2021 27
2022 10
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

1,903 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Mechanism of HIV-1 Entry.
Chen B. Chen B. Trends Microbiol. 2019 Oct;27(10):878-891. doi: 10.1016/j.tim.2019.06.002. Epub 2019 Jun 28. Trends Microbiol. 2019. PMID: 31262533 Free PMC article. Review.
HIV-1 envelope glycoprotein [Env; trimeric (gp160)(3) cleaved to (gp120/gp41)(3)] attaches the virion to a susceptible cell and induces fusion of viral and cell membranes to initiate infection. ...In this review, I summarize our latest understanding of the …
HIV-1 envelope glycoprotein [Env; trimeric (gp160)(3) cleaved to (gp120/gp41)(3)] attaches the virion to a susceptible …
A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160.
Lim RM, Rong L, Zhen A, Xie J. Lim RM, et al. ACS Chem Biol. 2020 Aug 21;15(8):2299-2310. doi: 10.1021/acschembio.0c00537. Epub 2020 Jul 28. ACS Chem Biol. 2020. PMID: 32667183 Free PMC article.
However, current anti-HIV CARs are limited by targeting a single epitope of the HIV envelope glycoprotein gp160, which cannot counter the enormous diversity and mutability of viruses. ...Given that numerous anti-gp160 antibodies with different a …
However, current anti-HIV CARs are limited by targeting a single epitope of the HIV envelope glycoprotein gp160, …
Dendronized Gold Nanoparticles as Carriers for gp160 (HIV-1) Peptides: Biophysical Insight into Complex Formation.
Garaiova Z, Melikishvili S, Michlewska S, Ionov M, Pedziwiatr-Werbicka E, Waczulikova I, Hianik T, Gomez-Ramirez R, de la Mata FJ, Bryszewska M. Garaiova Z, et al. Langmuir. 2021 Feb 2;37(4):1542-1550. doi: 10.1021/acs.langmuir.0c03159. Epub 2021 Jan 21. Langmuir. 2021. PMID: 33475368
In this study, three different dendronized gold nanoparticles (AuNPs 13-15) were investigated for a complexation ability with gp160 synthetic peptides derived from an HIV envelope. It has been shown that HIV peptides interacted with nanoparticles as ev …
In this study, three different dendronized gold nanoparticles (AuNPs 13-15) were investigated for a complexation ability with gp160 s …
Mapping out the intricate relationship of the HIV envelope protein and the membrane environment.
Klug YA, Rotem E, Schwarzer R, Shai Y. Klug YA, et al. Biochim Biophys Acta Biomembr. 2017 Apr;1859(4):550-560. doi: 10.1016/j.bbamem.2016.10.012. Epub 2016 Oct 25. Biochim Biophys Acta Biomembr. 2017. PMID: 27793589 Free article. Review.
The HIV gp160 envelope fusion protein is situated in the viral membrane and mediates virus entry into its host cell. ...Protein-lipid interactions and membrane properties influence the dynamics of a manifold of gp160 biological activities …
The HIV gp160 envelope fusion protein is situated in the viral membrane and mediates virus entry into its host c …
Intramolecular quality control: HIV-1 envelope gp160 signal-peptide cleavage as a functional folding checkpoint.
McCaul N, Quandte M, Bontjer I, van Zadelhoff G, Land A, Crooks ET, Binley JM, Sanders RW, Braakman I. McCaul N, et al. Cell Rep. 2021 Aug 31;36(9):109646. doi: 10.1016/j.celrep.2021.109646. Cell Rep. 2021. PMID: 34469718 Free article.
While generally thought to be removed co-translationally, we report two additional post-targeting functions for the HIV-1 gp120 signal peptide, which remains attached until gp120 folding triggers its removal. ...Considering the 15% proteins with signal peptides and the fre …
While generally thought to be removed co-translationally, we report two additional post-targeting functions for the HIV-1 gp120 signa …
Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.
Gartland M, Arnoult E, Foley BT, Lataillade M, Ackerman P, Llamoso C, Krystal M. Gartland M, et al. J Antimicrob Chemother. 2021 Oct 11;76(11):2958-2964. doi: 10.1093/jac/dkab257. J Antimicrob Chemother. 2021. PMID: 34297843 Free PMC article.
BACKGROUND: Fostemsavir, a prodrug of the gp120-directed attachment inhibitor temsavir, is indicated for use in heavily treatment-experienced individuals with MDR HIV-1. Reduced susceptibility to temsavir in the clinic maps to discrete changes at amino acid positions in …
BACKGROUND: Fostemsavir, a prodrug of the gp120-directed attachment inhibitor temsavir, is indicated for use in heavily treatment-experience …
Presence of IgG anti-gp160/120 antibodies confers higher HIV capture capacity to erythrocytes from HIV-positive individuals.
Garcia MN, dos Ramos Farias MS, Fazzi L, Grasso D, Rabinovich RD, Ávila MM. Garcia MN, et al. PLoS One. 2012;7(9):e45808. doi: 10.1371/journal.pone.0045808. Epub 2012 Sep 25. PLoS One. 2012. PMID: 23049866 Free PMC article.
BACKGROUND: HIV binding has been demonstrated in erythrocytes from HIV-positive and HIV-negative individuals. ...METHODOLOGY/PRINCIPAL FINDINGS: IgGs anti-HIV associated to erythrocytes were found in 77.3% (58/75) of the HIV-positive individuals …
BACKGROUND: HIV binding has been demonstrated in erythrocytes from HIV-positive and HIV-negative individuals. ...METHOD …
Immunisation with gp160 in HIV-1 infection.
Pontesilli O, Aiuti F. Pontesilli O, et al. Lancet. 1999 Sep 11;354(9182):948-9. doi: 10.1016/S0140-6736(05)75694-4. Lancet. 1999. PMID: 10489977 Clinical Trial. No abstract available.
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
Magaret CA, Benkeser DC, Williamson BD, Borate BR, Carpp LN, Georgiev IS, Setliff I, Dingens AS, Simon N, Carone M, Simpkins C, Montefiori D, Alter G, Yu WH, Juraska M, Edlefsen PT, Karuna S, Mgodi NM, Edugupanti S, Gilbert PB. Magaret CA, et al. PLoS Comput Biol. 2019 Apr 1;15(4):e1006952. doi: 10.1371/journal.pcbi.1006952. eCollection 2019 Apr. PLoS Comput Biol. 2019. PMID: 30933973 Free PMC article.
A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope (Env) amino acid (AA) sequence features. An exhaustive analysis that tests how PE depends on every AA feature with sufficient variation …
A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope …
HIV gp160 vaccine (Immuno AG).
[No authors listed] [No authors listed] Drugs R D. 1999 Jun;1(6):449-50. doi: 10.2165/00126839-199901060-00005. Drugs R D. 1999. PMID: 10566080 No abstract available.
1,903 results